Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
This strategy supports the company’s commitment to reach more than 200,000 patients in LMICs by 2033 with its innovative treatments.
- This strategy supports the company’s commitment to reach more than 200,000 patients in LMICs by 2033 with its innovative treatments.
- “Access to potentially life-saving innovative medicines is very limited in some parts of the world, leaving patients with few treatment options for serious diseases like cancer,” said Christopher Boerner , Ph.D., board chair and chief executive officer, Bristol Myers Squibb.
- “Bristol Myers Squibb believes patients who can benefit from our medicines should have access to them.
- Enabling timely access to innovative medicines in LMICs is part of BMS’ commitment to health equity globally and our Environmental, Social and Governance (ESG) strategy .